Patrys has today released its Quarterly Activities Report and 4C for the quarter ended 30 June 2021.
Our R&D program has continued to thrive, with significant progress in the development of our deoxymab antibodies.
Key achievements include:
- New pharmacokinetic data highlighting the potential to use PAT-DX1 and PAT-DX3 for different therapeutic applications
- Collaboration with Imagion Biosystems established to develop new, improved imaging agents for brain cancers using Patrys’ deoxymabs
- Preclinical data supporting potential for PAT-DX1 to be used for primary and secondary brain cancers published in peer-reviewed scientific journal
The Company has a strong financial position, with cash and short-term investment balance of $10.9 M on 30 June 202, following the receipt of $627k from the R&D Tax Incentive Refund scheme.